Home › BETA › Filing
🔔 Get instant alerts when BETA files quarterly results on BSE Start free trial →

Press Release

Filed: 19 Nov 2026, 11:27 IST Exchange: NSE Category: Merger/Acquisition — Oncology Joint Venture
Beta Drugs forms Oncology JV with IMGSA Groupe SPA in Algeria - JV acquires IMGSA’s oncology formulation plant for US$8.7 million - Beta holds 49% stake, manages JV operations; IMGSA holds 51% - Beta to infuse US$3 million over 3 years and transfer formulation technology - Plant qualified by Algerian FDA for national tender supply - JV targets Algeria and North African oncology markets using IMGSA's distribution - MD Rahul Batra: JV aims to improve access to quality cancer therapies in Algeria
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 BETA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add BETA to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Beta Drugs Limited

Important. The summary above is generated automatically from Beta Drugs Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.